Bausch Health Companies Inc.

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 18/07/2024 am IST			5-day change	1st Jan Change
7.62 ^USD	+0.93%		+4.10%	-4.99%

10/07	Raymond James Initiates Bausch Health at Market Perform Rating	MT
21/06	Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	MT

Bausch Health Companies Inc. Reduces Debt by Additional $100 Million

January 29, 2019

Bausch Health Companies Inc. announced it has paid down an additional $100 million of its senior secured term loans using cash generated from operations.

Latest news about Bausch Health Companies Inc.

Raymond James Initiates Bausch Health at Market Perform Rating	10/07	MT
Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	21/06	MT
Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"	17/06	MT
Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States	03/06	MT
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens	28/05	MT
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada	24/05	MT
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	17/05	CI
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	15/05	MT
Bausch Health Companies Inc. Approves Directorate Appointments	15/05	CI
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters	15/05	MT
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters	15/05	MT
RBC Noes Bausch Health Filing For Rehearing in Appellate Court	13/05	MT
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	03/05	MT
Bausch Health Shares Fall Following Q1 Results	02/05	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	02/05	MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	02/05	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	02/05	MT
Bausch Health Companies Inc. Reaffirms Earnings Guidance for the Full Year 2024	02/05	CI
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
North American Morning Briefing : Stock Futures -2-	02/05	DJ
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	02/05	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	01/05	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	01/05	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	01/05	MT

Chart Bausch Health Companies Inc.

Duration

Period

More charts

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

7.55 USD

Average target price

9.562 USD

Spread / Average Target

+26.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAUSCH HEALTH COMPANIES INC.	-4.99%	276.93Cr
ELI LILLY AND COMPANY	+55.35%	85TCr
NOVO NORDISK A/S	+31.64%	63TCr
JOHNSON & JOHNSON	-0.10%	36TCr
MERCK & CO., INC.	+15.47%	32TCr
ABBVIE INC.	+13.10%	30TCr
ASTRAZENECA PLC	+15.51%	24TCr
NOVARTIS AG	+16.72%	23TCr
AMGEN INC.	+16.54%	18TCr
PFIZER, INC.	+4.31%	17TCr

Other Pharmaceuticals